Clin2
NCT07239011Possibly a fitRecruiting

Dapagliflozin for depression study

Depression

Treatments studied

Part of Hormones & metabolism, Mental health clinical trials.

This trial tests whether dapagliflozin, a diabetes medication, can help treat major depression. It is for adults who have been depressed for at least 2 months and score high on a depression scale.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
60 people
Ages
18 years to 60 years
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have been feeling depressed for at least 2 months.
  • Your depression symptoms are severe (score above 18 on the Hamilton depression scale).
  • If you can become pregnant, you have a negative pregnancy test and use effective birth control.
  • You do not have bipolar disorder, a personality disorder, or an eating disorder.
  • You are not currently dependent on or abusing substances.
  • You do not have a history of seizures, recent electroconvulsive therapy (ECT), or an inflammatory disorder.
  • You are not allergic to dapagliflozin or similar medications.
  • You are not pregnant or breastfeeding.
  • You do not have diabetes or severe kidney problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06707012Recruiting· Phase 4
Metformin plus antidepressants for depression in obesity

This trial tests whether adding metformin (a diabetes medicine) to usual antidepressant treatment can help improve depression in people who are overweight or obese. It is for adults age 18–44 who are newly diagnosed with depression and do not have diabetes.

Karachi, Sindh
NCT06897605Recruiting· Phase 2
Dapagliflozin for anemia in kidney disease

This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.

Al Mansurah
NCT05757791Recruiting· Phase 2
Testing an SGLT2 diabetes drug for depression

This Phase 2 trial tests whether an SGLT2 medicine (like empagliflozin) can reduce symptoms of major depression. It may help people with moderate-to-severe depression who are otherwise eligible for the study.

New York, New York
NCT07472920Not yet recruiting
Empagliflozin for bipolar depression

This trial tests if empagliflozin (a diabetes drug) can help improve depression symptoms in people with bipolar disorder who also have insulin resistance. You take it alongside your current bipolar medications.

São Paulo, São Paulo
NCT05174052Recruiting· Phase 3
Dapagliflozin for heart rhythm problems in diabetes

This trial studies dapagliflozin, a diabetes medicine, to see if it can help people with paroxysmal atrial fibrillation (irregular heart rhythm). If you have both diabetes and this type of AF, the study may offer a chance to improve your heart rhythm and outcomes.

Oklahoma City, Oklahoma
NCT06286878Recruiting· Phase 2/Phase 3
Dapagliflozin after a heart attack: recovery study

This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.

São Paulo, São Paulo

Hear when a new Depression trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.